• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab.

作者信息

VandeVrede Lawren, La Joie Renaud, Horiki Sheena, Mundada Nidhi S, Koestler Mary, Hwang Ji-Hye, Ljubenkov Peter A, Rojas Julio C, Rabinovici Gil D, Boxer Adam L, Seeley William W

机构信息

Department of Neurology, Memory and Aging Center, University of California San Francisco, 675 Nelson Rising Lane, Suite 190, San Francisco, CA, 94158, USA.

Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.

出版信息

Acta Neuropathol. 2023 Nov;146(5):777-781. doi: 10.1007/s00401-023-02631-8. Epub 2023 Sep 19.

DOI:10.1007/s00401-023-02631-8
PMID:37725166
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10564667/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b57/10564667/e146b0f91c33/401_2023_2631_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b57/10564667/9faeed833ddd/401_2023_2631_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b57/10564667/b141a5ed5fd1/401_2023_2631_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b57/10564667/e146b0f91c33/401_2023_2631_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b57/10564667/9faeed833ddd/401_2023_2631_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b57/10564667/b141a5ed5fd1/401_2023_2631_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b57/10564667/e146b0f91c33/401_2023_2631_Fig3_HTML.jpg

相似文献

1
Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab.共同病理学可能会影响靶向淀粉样蛋白治疗的结果：两名接受阿杜卡单抗治疗患者的临床病理结果
Acta Neuropathol. 2023 Nov;146(5):777-781. doi: 10.1007/s00401-023-02631-8. Epub 2023 Sep 19.
2
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.阿杜卡努单抗在降低淀粉样蛋白的同时产生了具有临床意义的益处。
Alzheimers Res Ther. 2021 May 10;13(1):98. doi: 10.1186/s13195-021-00838-z.
3
"Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.阿杜卡奴单抗在阿尔茨海默病中的卷土重来：陈酒换新瓶。
Biomed Pharmacother. 2022 Apr;148:112746. doi: 10.1016/j.biopha.2022.112746. Epub 2022 Feb 26.
4
Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease.EMERGE 和 ENGAGE 三期临床试验中阿杜卡奴单抗治疗早期阿尔茨海默病患者的日本亚组分析
J Prev Alzheimers Dis. 2024;11(5):1260-1269. doi: 10.14283/jpad.2024.106.
5
Profiling aducanumab as a treatment option for Alzheimer's disease: an overview of efficacy, safety and tolerability.评估 aducanumab 作为阿尔茨海默病治疗选择的情况：疗效、安全性和耐受性概述。
Expert Rev Neurother. 2024 Nov;24(11):1045-1053. doi: 10.1080/14737175.2024.2402058. Epub 2024 Sep 18.
6
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.在两项评估早期阿尔茨海默病患者使用 aducanumab 的 3 期研究中，淀粉样蛋白相关成像异常。
JAMA Neurol. 2022 Jan 1;79(1):13-21. doi: 10.1001/jamaneurol.2021.4161.
7
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.两项早期阿尔茨海默病中阿杜卡努单抗的随机 3 期研究。
J Prev Alzheimers Dis. 2022;9(2):197-210. doi: 10.14283/jpad.2022.30.
8
Aducanumab: The first targeted Alzheimer's therapy.阿杜卡努单抗：首款靶向阿尔茨海默病疗法。
Drug Discov Ther. 2021;15(3):166-168. doi: 10.5582/ddt.2021.01061.
9
Aducanumab: First Approval.阿杜卡奴单抗：首次获批
Drugs. 2021 Aug;81(12):1437-1443. doi: 10.1007/s40265-021-01569-z.
10
Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice.用阿杜卡单抗进行免疫疗法可恢复Tg2576小鼠的钙稳态。
J Neurosci. 2016 Dec 14;36(50):12549-12558. doi: 10.1523/JNEUROSCI.2080-16.2016. Epub 2016 Nov 3.

引用本文的文献

1
Brain-derived extracellular vesicle microRNAs in Lewy body and Alzheimer's disease.路易体病和阿尔茨海默病中脑源性细胞外囊泡微小RNA
bioRxiv. 2025 Jun 9:2025.06.06.656900. doi: 10.1101/2025.06.06.656900.
2
Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease.阿尔茨海默病生物学和临床分期修订标准的评估
JAMA Neurol. 2025 May 19. doi: 10.1001/jamaneurol.2025.1100.
3
A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research.淀粉样蛋白PET百分标准值在临床试验和研究中的实际应用概述。

本文引用的文献

1
Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.一名接受lecanemab治疗并因中风接受t-PA治疗的患者发生多处脑出血。
N Engl J Med. 2023 Feb 2;388(5):478-479. doi: 10.1056/NEJMc2215148. Epub 2023 Jan 4.
2
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
3
Alzheimer disease neuropathology in a patient previously treated with aducanumab.阿杜卡努单抗治疗后的阿尔茨海默病患者的神经病理学。
Neuroimage Clin. 2025 Mar 10;46:103765. doi: 10.1016/j.nicl.2025.103765.
4
Capillary basal lamina in human brain and spinal cord has fibrillar collagen type I and type III: Ignorance may not be bliss.人类大脑和脊髓中的毛细血管基膜含有I型和III型纤维状胶原蛋白：无知可能并非幸福。
Free Neuropathol. 2025 Feb 18;6:6. doi: 10.17879/freeneuropathology-2025-6159. eCollection 2025 Jan.
5
Can brain network connectivity facilitate the clinical development of disease-modifying anti-Alzheimer drugs?脑网络连通性能否促进疾病修饰性抗阿尔茨海默病药物的临床开发？
Brain Commun. 2024 Dec 18;7(1):fcae460. doi: 10.1093/braincomms/fcae460. eCollection 2025.
6
Blood biomarkers of Alzheimer's disease: important considerations for use in clinical practice.阿尔茨海默病的血液生物标志物：临床实践应用中的重要考量因素。
Neural Regen Res. 2025 Jan 1;20(1):205-206. doi: 10.4103/NRR.NRR-D-23-02017. Epub 2024 Apr 3.
7
Degree of amyloid-β burden could be indicative of the primary etiology underlying dementia.β淀粉样蛋白负荷程度可能表明痴呆症潜在的主要病因。
Eur J Nucl Med Mol Imaging. 2025 Jan;52(2):782-784. doi: 10.1007/s00259-024-06875-8. Epub 2024 Aug 30.
8
Clinicopathological correlation of cerebrospinal fluid alpha-synuclein seed amplification assay in a behavioral neurology autopsy cohort.在行为神经病理学尸检队列中，脑脊液α-突触核蛋白种子扩增检测的临床病理相关性。
Alzheimers Dement. 2024 May;20(5):3334-3341. doi: 10.1002/alz.13799. Epub 2024 Mar 27.
9
Alzheimer's disease (AD) co-pathology in dementia with Lewy bodies (DLB): implications in the disease modification era.路易体痴呆（DLB）中的阿尔茨海默病（AD）共病病理：在疾病修饰时代的意义
Eur J Nucl Med Mol Imaging. 2024 Jun;51(7):2151-2153. doi: 10.1007/s00259-024-06619-8. Epub 2024 Jan 29.
Acta Neuropathol. 2022 Jul;144(1):143-153. doi: 10.1007/s00401-022-02433-4. Epub 2022 May 17.
4
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.两项早期阿尔茨海默病中阿杜卡努单抗的随机 3 期研究。
J Prev Alzheimers Dis. 2022;9(2):197-210. doi: 10.14283/jpad.2022.30.
5
Donanemab in Early Alzheimer's Disease.多奈单抗用于早期阿尔茨海默病
N Engl J Med. 2021 May 6;384(18):1691-1704. doi: 10.1056/NEJMoa2100708. Epub 2021 Mar 13.
6
Multisite study of the relationships between antemortem [C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology.多中心研究生前 [C]PIB-PET 百分位值与阿尔茨海默病神经病理学死后测量值之间的关系。
Alzheimers Dement. 2019 Feb;15(2):205-216. doi: 10.1016/j.jalz.2018.09.001. Epub 2018 Oct 19.
7
Estimation of amyloid distribution by [F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition.[F]氟替美莫 PET 对淀粉样蛋白分布的评估可预测淀粉样 β 蛋白沉积的神经病理学阶段。
Acta Neuropathol. 2018 Oct;136(4):557-567. doi: 10.1007/s00401-018-1897-9. Epub 2018 Aug 19.
8
Longitudinal tau PET in ageing and Alzheimer's disease.tau 蛋白 PET 成像在衰老和阿尔茨海默病中的应用
Brain. 2018 May 1;141(5):1517-1528. doi: 10.1093/brain/awy059.
9
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.阿杜卡努单抗可减少阿尔茨海默病中的 Aβ 斑块。
Nature. 2016 Sep 1;537(7618):50-6. doi: 10.1038/nature19323.